MediWound receives pediatric indication for burn remedy NexoBrid (NASDAQ:MDWD)


Scar and scab (eschar) on asian female knee

lzf/iStock through Getty Photographs

  • The U.S. FDA has accredited use of MediWound’s (NASDAQ:MDWD) burn remedy NexoBrid in pediatric sufferers as younger as newborns.
  • NexoBrid (anacaulase) is meant for elimination of eschar — lifeless tissue that kinds over wholesome pores and skin — for sufferers with deep partial- and/or full-thickness thermal burns.

Leave a Reply

Your email address will not be published. Required fields are marked *